AKERO THERAPEUTICS INC's ticker is AKRO and the CUSIP is 00973Y108. A total of 69 filers reported holding AKERO THERAPEUTICS INC in Q1 2020. The put-call ratio across all filers is - and the average weighting 1.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,058,000 | +54.8% | 100,000 | +42.9% | 0.70% | +72.8% |
| Q2 2023 | $3,268,300 | +22.0% | 70,000 | 0.0% | 0.40% | -25.0% |
| Q1 2023 | $2,678,200 | -30.2% | 70,000 | 0.0% | 0.54% | -32.9% |
| Q4 2022 | $3,836,000 | -51.0% | 70,000 | -69.6% | 0.80% | -47.1% |
| Q3 2022 | $7,832,000 | +187.7% | 230,000 | -20.2% | 1.52% | +171.6% |
| Q2 2022 | $2,722,000 | -4.1% | 288,058 | +44.0% | 0.56% | -24.1% |
| Q1 2022 | $2,838,000 | +57.8% | 200,000 | +135.3% | 0.74% | +48.2% |
| Q4 2021 | $1,798,000 | -5.4% | 85,000 | 0.0% | 0.50% | -8.8% |
| Q3 2021 | $1,900,000 | -9.9% | 85,000 | 0.0% | 0.55% | -6.0% |
| Q2 2021 | $2,109,000 | -14.5% | 85,000 | 0.0% | 0.58% | -17.6% |
| Q1 2021 | $2,466,000 | +12.4% | 85,000 | 0.0% | 0.70% | +8.1% |
| Q4 2020 | $2,193,000 | -16.2% | 85,000 | 0.0% | 0.65% | -18.5% |
| Q3 2020 | $2,617,000 | +105.7% | 85,000 | +41.7% | 0.80% | +42.9% |
| Q1 2020 | $1,272,000 | – | 60,000 | – | 0.56% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Skorpios Trust | 3,271,829 | $179,296 | 57.03% |
| Redmile Group, LLC | 2,632,912 | $144,283,578 | 5.90% |
| Avidity Partners Management LP | 3,825,000 | $209,610,000 | 4.54% |
| COMMODORE CAPITAL LP | 537,076 | $29,432 | 4.44% |
| Atlas Venture Life Science Advisors, LLC | 594,251 | $32,564,955 | 3.92% |
| Paradigm Biocapital Advisors LP | 604,544 | $33,129,011 | 3.89% |
| Yiheng Capital Management, L.P. | 1,468,905 | $80,495,994 | 3.56% |
| Altium Capital Management LP | 125,000 | $6,850,000 | 3.48% |
| Tri Locum Partners LP | 128,851 | $7,061,000 | 2.86% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 172,100 | $9,431,080 | 2.70% |